SCCM Resource Library-Novel Immunomodulators for Sepsis: Will We Get One?

Video Transcription

Video Summary

The video discusses the ongoing challenges and potential solutions in developing effective immune modulators for sepsis treatment. Despite the hope that a novel treatment will emerge, current research has not yet yielded a definitive breakthrough. The speaker highlights the complex nature of sepsis, involving both hyper-inflammatory and immune-paralyzed states, and the need for personalized medicine approaches rather than one-size-fits-all strategies. Several immune modulators, such as anakinra, anti-TNF alpha agents, and interleukin-7, have shown promise in trials but have not demonstrated significant mortality benefits due to the lack of precise patient targeting. A key takeaway is the necessity of understanding patients' real-time immune profiles to direct therapies effectively. Future trials, like the PRECISE trial in children, may offer insights by customizing treatment based on immune defects, aiming for personalized interventions to improve outcomes in sepsis management.

Asset Caption

One-Hour Concurrent Session | Dysregulated Care: How to Improve Sepsis Outcomes

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

sepsis treatment

immune modulators

personalized medicine

immune profiles

PRECISE trial

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.